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Abstract
We provide a summary of the current status of the human immunodeﬁciency virus (HIV) epidemic, including data on the transmission of
drug-resistant virus in the European Region of the WHO. The review was conducted by searching the reports of the European Centre for
Disease Prevention and Control and the United Nations General Assembly Special Session country reports to identify the number of HIV
cases reported in 2002–2011, the number of HIV tests performed, and the results of the most recent HIV surveys in at-risk groups. In the
West, a 5-year linear trend analysis suggests an increase in the number of reported HIV cases in Belgium, Greece, and Iceland, and a decline
in The Netherlands, Ireland, Portugal, Switzerland, and the UK. In the Centre, the number of reported cases increased in Bulgaria and
Turkey, and in the East, the number of reported cases increased in Armenia, Georgia, and Ukraine. Estonia and Latvia reported a signiﬁcant
downward trend. HIV transmission in men who have sex with men (MSM) and heterosexual transmission accounted for, respectively, 40%
and 38% of newly reported HIV cases in the West in 2011, whereas the epidemic in the Centre is predominantly concentrated in MSM.
Although injection drug use remains the key driving force of the epidemic in the East, there is increasing evidence of sexual transmission
from the core groups of injection drug users, and increasing spread within MSM. The pattern of transmitted drug resistance (TDR) is
heterogeneous accross Europe; a signiﬁcant number of clusters of TDR have been recently observed in several European countries.
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Introduction
Human immunodeﬁciency virus (HIV) infection is one of the
major public health issues in Europe. According to the Joint
United Nations Programme on HIV/AIDS (UNAIDS), in 2011
900 000 (830 000–1 000 000) adults and children were living
with HIV in the countries of western and central Europe, and
1 400 000 (1 100 000–1 800 000) in the countries of eastern
Europe and Central Asia [1]. In 2011, an estimated 30 000
(21 000–40 000) new HIV infections occurred in western and
central Europe, and 7000 (6100–7500) people died of AIDS. In
the same year, it was estimated that there were 140 000
(91 000–210 000) new HIV infections in East and Central Asia,
and 92 000 (63 000–120 000) deaths from AIDS.
According to the data of the European Centre for Disease
Prevention and Control (ECDC), 53 974 HIV cases were
reported in the European Region of the WHO (WHO EURO)
(West—Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, Luxermbourg, Malta, The Netherlands,
Portugal, Spain, Sweden, the UK, Iceland, Norway, Andora,
Israel, Monaco, San Marino, and Switzerland; East—Armenia,
Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan,
Latvia, Lithuania, Republic of Moldova, Russian Federation,
Tajikistan, Turkmenistan, Ukraine, and Uzbekistan; Centre—
Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus,
Czech Republic, Hungary, the Former Yugoslav Republic of
Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia,
Slovenia, Turkey) in 2011 [2]. Of these, 48.5% were reported
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in the West, 45.9% in the East, and 5.6% in the Centre. In
addition, 67 317 HIV cases were reported in the Russian
Federation in 2011. In a decade (comparing the year 2011 with
the year 2002), the absolute number of reported HIV cases
increased by 89.4%, suggesting a changing pattern of the HIV
epidemic across the Region [2,3].
The main modes of HIV transmission vary substantially
across the Region. The dominant reported mode of transmis-
sion in the East in 2011 was heterosexual (56.7%), whereas, in
the West and the Centre, transmission resulting from to
male-to-male sex predominated (40.1% and 27.3%, respec-
tively) [2]. Notable differences exist across the Region with
respect to the male-to-female ratio of the reported HIV cases;
in 2011, the ratios were 1.3 : 1 in the East, 2.9 : 1 in the West,
and 4.3 : 1 in the Centre.
There are also substantial regional differences in HIV-re-
lated morbidity: whereas the rates of reported AIDS cases
were 1.0/100 000 and 0.4/100 000 in 2011 in the West and
Centre, respectively, the rate was as high as 5.7/100 000 in the
East [2].
The aim of this article is to present the recent changes in
the HIV epidemics in Europe, with a particular focus on the
countries where signiﬁcant increases and/or a high number of
new HIV diagnoses have been reported or where decreases in
the reported HIV cases have been recorded since 2002. We
also brieﬂy review recent data on the transmission of
drug-resistant HIV in Europe.
Methods
We reviewed the reports of the ECDC (for the period 2007–
2011) and the reports of the European Centre for the
Epidemiological Monitoring of AIDS (for the period 2002–
2006) to identify the number of reported cases of HIV in the
period 2002–2011 and the number of HIV tests performed per
1000 population. The data on HIV testing had to be sought for
the years 2000 and 2001, as a number of countries did not
report this data for the year 2002.
Linear regression was performed with STATA V.11.0 to
calculate the trend in the reported new HIV diagnoses in a
10-year period (from 2002 to 2011) and in a 5-year period
(2007–2011) [4]. The United Nations General Assembly
Special Session (UNGASS) country reports on HIV and Global
AIDS Response Country Progress reports were reviewed to
ﬁnd the most recent data on HIV prevalence from cross-sec-
tional surveys. The literature review was also conducted with
PubMed. The terms included were those relating to HIV
infection, resistance to antiretrovirals, and the selected
countries. The search included MESH terms and text words
to enhance the retrieval of relevant studies. The language was
limited to English, and we searched for manuscripts published
since the year 2007.
The summaries of the HIV epidemic are provided for the
following countries according to the WHO EURO classiﬁca-
tion of the European Region: West—Belgium, Greece, Portu-
gal, the UK, Switzerland, France, Spain, Italy, and Germany;
Centre—Albania, Bulgaria, Cyprus, Czech Republic, Slovenia,
and Turkey; East—Estonia, Latvia, Lithuania, Azerbaijan,
Armenia, Georgia, Moldova, Russian Federation, and Ukraine.
The countries of Central Asia were not included in the
narrative review.
HIV Surveillance Data
Figs 1–3 show the number of newly reported HIV cases per
100 000 population in the period 2002–2011 by region. There
was a signiﬁcant increase in the number of reported HIV cases
in the Centre in both the 5-year period (2007–2011) and the
10-year period (2002–2011). In the West, there was a
declining trend in the past 5 years; in the East, there was a
signiﬁcant increase in the past 10 years.
West: Continuing High HIV Transmission in
Men Who Have Sex with Men (MSM)
Western European countries are considered to have a
long-lasting, mature HIV epidemic; however, there has been
little overall evidence of a reversal of the epidemic. In 2002,
the rate of newly reported infections in the West was 6.5 per
100 000 inhabitants, whereas 10 years later the rate was the
same (Fig. 1). Of 26 204 new infections reported in 2011,
74.4% were in males [2]. In 2011, 3905 AIDS cases and 955
deaths from AIDS were reported (Table 1). The most
common AIDS indicator disease in 2011 was Pneumocystis
pneumonia (diagnosed in 27.2% of AIDS cases), followed by
oesophageal candidiasis and Kaposi’s sarcoma.
The overall average rate of HIV infection in the West in
2011 was 4.1 times higher than that in the Centre [2]. As in
other regions, there was considerable variation in the rates of
HIV infection between countries and within countries. Sexual
transmission was the main mode of transmission: sex between
men accounted for 40.1% and sex between men and women
for 37.9% of new infections in 2011 [2]. Several countries had a
rate of reported infections in 2011 that was considerably
higher than the average for the region (per 100 000 inhabit-
ants: Belgium, 10.7; UK, 10.0, Portugal, 8.5; and Spain, 8.4). A
formal 5-year and 10-year linear trend analysis of the rate of
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 917–929
918 Clinical Microbiology and Infection, Volume 19 Number 10, October 2013 CMI
reported cases suggests an increasing trend in Belgium,
Greece, and Iceland, a declining trend in The Netherlands,
Ireland, Portugal, Switzerland, and the UK, and no change in
Denmark, Finland, Germany, Israel, Malta, Norway, and
Sweden. It is challenging to assess the 5-year or 10-year trend
of reported HIV infections in Italy and Spain, as HIV case
reporting in these two countries does not have national
coverage [2].
In the West, a signiﬁcant proportion of heterosexually
acquired cases originated from persons from countries with a
generalized HIV epidemic. For example, in 2011, >61.9% of
heterosexually acquired cases in Belgium were reported in
persons originating from countries with a generalized epidemic
[2]. However, the increasing number of newly reported
infections in Belgium is mostly attributable to an increasing
epidemic among MSM, whereas a decline in infections acquired
through sex between men and women has been observed
[2,5]. A recent venue-based cross-sectional study using time–
location sampling found that the HIV prevalence in MSM who
attended different types of venue ranged from 1.4% at younger
MSM venues, to 4.9% at more general gay venues, to a high of
14.5% at cruising venues [6].
FIG. 1. Annual rates of reported HIV infections per 100 000 inhabitants in 19 countries of the WHO region of Western Europe (West) for the
period 2002 to 2011. The black line represents a linear trend line for the region. Data source: ECDC/WHO Regional Ofﬁce for Europe. HIV/AIDS
surveillance in Europe 2011. Stockholm: ECDC; 2012.
FIG. 2. Annual rates of reported HIV infections per 100 000 inhabitants in 15 countries of the WHO region of central Europe (Centre) for the
period 2002 to 2011. The black line represents a linear trend line for the region. BH, Bosnia and Herzegovina. Data source: ECDC/WHO Regional
Ofﬁce for Europe. HIV/AIDS surveillance in Europe 2011. Stockholm: ECDC; 2012.
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In Greece, the rate of new infections was 7.4/100 000 in
2011 [2]. An outbreak among injection drug users (IDUs)
occurred in 2011, and was the main reason for a 35.7%
increase in reported HIV cases in 2011 as compared with 2010
[2,7]. Of all cases reported to the ECDC (n = 837) in 2011,
84.9% were males, and MSM accounted for 34.1% of cases. The
HIV prevalence among MSM was estimated to be 6.5% [8].
The declining trend in reported HIV infections in Portugal in
recent years is mainly attributable to fewer infections among
individuals acquiring HIV through heterosexual contact and
injection drug use. However, Portugal is still a country with a
relatively high annual rate of reported infections (8.5/100 000
in 2011); in 2011, 63.9% of 902 cases were reported as
resulting from heterosexual contact, 27.0% in MSM, and 6.9%
in IDUs [2]. There seems to be a discrepancy between the
relatively low number of cases reported in MSM and the
results of a survey based on snowball and Internet sampling
that found an HIV prevalence of 11.0% [8].
There is a declining trend in reported HIV infections in the
UK; however, the annual rate in 2011 (10/100 000) was still
among the highest in the West [2]. This decreasing trend is
explained mainly by fewer numbers of reported infections
among those born outside of the UK. The highest rates were
reported in MSM (47/1000) and the black African community
(37/1000) [9]. Of 6280 new infections reported in 2011, 71.1%
were in males, and the main transmission modes were sex
between men (48%) and heterosexual contact (48%) [9].
However, the annual number of new HIV infections among
MSM has been increasing since 2007, and reached 3010 cases
in 2011. In a CD4-staged back-calculation model of HIV
incidence, no evidence of a decline in incidence among MSM
was observed over the period 2001–2010, with between 2300
and 2500 new infections per year [10]. The estimated
model-based calculations suggest a 5.3% prevalence of HIV
infection in MSM [8].
Switzerland has had a decreasing annual rate of newly
reported infections over the past 5 years, and the rate was
7.1/100 000 in 2011 [2]. There are, however, different
dynamics between risk groups and time-spans, so the number
of new HIV diagnoses among MSM rose until 2008 and has
been declining since 2009. In persons with heterosexually
acquired HIV infection, particularly among women, a decline in
newly reported HIV infections has been observed since 2004.
As in other European countries, the proportion of non-Swiss
nationals among persons acquiring HIV through heterosexual
contact was high (68%) as compared with the MSM group
(40%) [11].
In France, the number of reported HIV infections in 2011
was 6.3/100 000 [2]. The epidemic is mainly driven by new
infections among MSM. A population-based HIV-1 incidence
modelling analysis for the period 2003–2008 showed a
persistent and high incidence of HIV in MSM. In all other
vulnerable populations, the HIV incidence declined [12].
The rate of new HIV infections in Spain in 2011 (8.4/
100 000) was considerably higher than the average for the
West [2]. In 2011, 2759 new HIV diagnoses were notiﬁed,
mostly in men (83.4%), and the major mode of transmission
was sex between men (53.7%). The prevalence of HIV among
MSM was relatively high in both serosurveys (17.0%) and in an
Internet-based survey (14.9%) [8].
Although the rate of newly reported infections in Italy has
declined recently, the absolute number of notiﬁed cases is
FIG. 3. Annual rates of reported HIV infections per 100 000 inhabitants in 14 countries of the WHO region of Eastern Europe and central Asia
(East) for the period 2002 to 2011. The black line represents a linear trend line for the region. Data source: ECDC/WHO Regional Ofﬁce for Europe.
HIV/AIDS surveillance in Europe 2011. Stockholm: ECDC; 2012.
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higher because of the greater coverage of the surveillance
system. There were 3461 cases notiﬁed in 2011, whereas in
2007 and 2002, 2227 and 1472 cases were reported,
respectively. The epidemic in Italy has changed over time;
there is a declining trend in reported infections in IDUs and an
increasing number of sexually acquired HIV infections (via both
heterosexual sex and sex between men) [13].
Germany has a relatively low annual rate of new
infections (3.5/100 000) [2]. According to a report of the
Robert Koch Institute, the modelled estimated annual
number of new HIV infections increased from approximately
2000 in 2001 to approximately 3400 in 2007, and then
declined to 2700 in 2011 [14]. New infections continue to
be mostly associated with MSM. Data modelling suggests
that the HIV incidence among MSM started to decline as of
2007 [14]. The HIV prevalence in MSM is estimated to be
between 5.0% and 7.5% [14].
Centre: Low-level HIV Epidemics but
Evidence of Increases in Transmission
In 2011, the rate of newly reported infections in the Centre
was 1.6 per 100 000 inhabitants as compared with 0.6 in 2002
(Fig. 2). Of 2997 new infections reported in 2011, 79.1% were
in males [2]. Linear 10-year trend analysis suggested signiﬁcant
increases in the numbers of reported cases in all countries of
the Centre except for Romania and Bosnia and Herzegovina,
and a 5-year trend analysis showed signiﬁcant increases in
Bulgaria and Turkey.
In 2011, there were 736 newly reported cases of AIDS and
362 cases of deaths from AIDS (Table 1). The most common
AIDS indicator disease in 2011 was wasting syndrome
(diagnosed in 28.4% of AIDS cases), followed by pulmonary
tuberculosis and Pneumocystis pneumonia.
TABLE 1. Summary of the human immunodeﬁciency virus (HIV)/AIDS epidemic in Europe
Characteristic
Region
West Centre East All Europe
Estimated number of people living
with HIV/AIDS in 2011a
900 000 (range: 830 000–1 000 000)b 1.4 million
(range: 1.1–1.8 million)
2.3 million
Total number of new diagnoses
in 2011 and proportional
contribution by regionsc
48.5% 5.6% 45.9% 53 974
Rate of newly reported HIV cases in 2011c 6.5/100 000 1.6/100 000 22.4/100 000 7.6/100 000
Trend in new diagnoses in the last 10 yearsc Stable (no evidence of a decrease) Increasing Increasing –
Proportion of male/female reported HIV cases 74/26 81/19 57/43 67/33
Major mode of transmission in 2011c Sex between men: 40.1%
Heterosexual: 37.9% (>1/3 of
heterosexually acquired infections are
from migrants from countries with
generalized HV epidemics)e
Sex between men: 27.3%d
Heterosexual: 25.7%
Intravenous drug use: 37.6%
Heterosexual: 56.7%
–
Number of reported AIDS cases in 2011 3905f 736 6282g –
Trend in AIDS diagnosis Considerable decline Heterogeneoush Increasing –
Number of AIDS deaths 955 362 1359 –
Most common AIDS indicator
diseases in 2011
Pneumocystis pneumonia (27.2%)
Oesophageal candidiasis (14.1%)
Kaposi’s sarcoma (9.1%)
Wasting syndrome (28.4%)
Pulmonary tuberculosis (19.4%)
Pneumocystis pneumonia (14.6%)
Pulmonary tuberculosis
(36.1%)
Wasting syndrome (25.4%)
Oesophageal candidiasis
(22.6%)
–
Late presentation to carei – – – 28.8%i,j; 37.7%k,j
48.9%i,l; 61.7%k,l
HIV infection among patients
with tuberculosis in 2011m
0–16.7%n 0–0.3%o 1.2–18.5%p
EU/EEA, European Union and European Economic Area countries.
aUNAIDS Report on the Global AIDS Epidemic, 2012.
bEstimate includes West and Centre.
cEuropean Centre for Disease Prevention and Control report (data not available from Monaco, Russian Federation,Uzbekistan, and Liechtenstein).
dSex between men probably under-reported.
eFrom countries with generalized epidemics.
fNo data from Sweden and Monaco.
gNo data from Russia and Uzbekistan.
hIncrease in Bulgaria, Hungary, Albania, and Turkey; decrease in Poland, Serbia, and Romania.
iData from EU/EEA countries.
jFewer than 200 CD4 cells per microlitre.
kData from non-EU/EEA countries.
lFewer than 350 CD4 cells per microlitre.
mTuberculosis surveillance and monitoring in Europe 2013. Stockholm, European Centre for Disease Prevention and Control, 2013 (http://www.euro.who.int/tuberculosis-
surveillance-and-monitoring-2013). Only countries with both reported percentage and with >50% of tuberculosis cases tested for HIV are included.
nBelgium, Iceland, Israel, Malta, and Spain.
oBulgaria, Montenegro, Slovakia, and Slovenia.
pArmenia, Azerbaijan, Belarus, Estonia, Kazakhstan, Latvia, Moldova, Tajikistan, Ukraine, and Uzbekistan.
Countries of the West (n = 23): Andorra, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, The
Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, the UK.
Countries of the Centre (n = 15): Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, the former Yugoslav Republic of Macedonia, Montenegro,
Poland, Romania, Serbia, Slovakia, Slovenia, and Turkey.
Countries of the East (n = 15): Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Tajikistan,
Turkmenistan, Ukraine, and Uzbekistan.
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In 2011, the highest number of reported HIV cases in the
Centre was in Cyprus (6.4/100 000), followed by Bulgaria and
Slovenia (2.7/100 000) [2]. In 2011, the male-to-female ratio in
newly reported HIV cases ranged from 2.4 : 1 in Romania to
15.3 : 1 in Slovakia.
HIV prevalence data in the UNGASS country reports for
2010–2011 were not available for Albania, Cyprus, and Turkey.
In Albania, 2.2 cases of HIV were reported per 100 000
population in 2011, which is a steady increase from the 0.7
cases reported in 2002 [2,3]. The most commonly reported
mode of transmission in newly reported cases in 2011 was
heterosexual transmission (83.1%), and the male-to-female
ratio in newly reported cases was 2.7 : 1. A study using
convenience sampling conducted in 2008 in Tirana in 90 female
sex workers (FSWs) found an HIV prevalence of 1.1% [15]. In
the same year, respondent-driven sampling (RDS) surveys
found no HIV cases among IDUs, whereas the HIV prevalence
among MSM was 1.8% [16].
The most common modes of transmission in newly
reported HIV cases in Bulgaria in 2011 were heterosexual
transmission (44.3%) and injection drug use (31.3%) [2]. The
highest measured HIV prevalence in surveys conducted in
2009 was in IDUs (7.1%), followed by MSM (0.6%) [17]. This
might imply an increase in the HIV prevalence in IDUs, as a
survey conducted in 2003 in 773 IDUs in Soﬁa using
convenience sampling found that 0.5% of IDUs were infected
[18].
The rate of new HIV infections in Cyprus in 2011 (6.4/
100 000) was considerably higher than in 2002 (2.3/100 000)
[2,3]. MSM contributed most of the newly reported HIV cases
(50.0%), followed by heterosexuals (40.7%).
The vast majority of newly diagnosed HIV cases in the
Czech Republic in 2011 were MSM (73.9%) [2]. The most
recent surveys, performed in 2010, found HIV prevalence rates
of 0.2% in IDUs, 4.8% in MSM, and 0.1% in FSWs [19]. Earlier
studies performed in the mid-2000s in several cities using
convenience sampling in 585 FSWs and 462 IDUs found HIV
prevalence rates of 0.7% and 0.2%, respectively [20].
Sex between men was the most common HIV transmission
category (63.6%) in 2011 in Slovenia, followed by heterosexual
transmission (14.5%). [2]. The HIV prevalence among MSM
was 2.2% according to sentinel surveillance and 5.1% in a
survey using time–location sampling, both conducted in 2009
[21,22].
The reported rate of HIV infection in Turkey in 2011 was
0.9/100 000. The vast majority of cases in 2011 had an
unknown mode of transmission reported (60.4%), followed by
heterosexual contact (38.3%). Although no case of HIV in MSM
was reported in 2011, the male-to-female ratio in newly
reported cases was 2.9 : 1.
East: Transmission from IDUs Sustains the
Heterosexual Epidemic
In 2011, the rate of newly reported infections in the East was
22.4/100 000, which was markedly higher than a decade
previously (8.8/100 000 in 2002) (Fig. 3). Of 24 773 HIV
infections reported in 2011, 57.4% were in men [2]. All
countries of the East registered a signiﬁcant increase in newly
diagnosed HIV cases in the past 10 years, with the exception
of Estonia and Latvia, which had a signiﬁcant downward trend
(no signiﬁcant difference was found for Lithuania). Similarly, a
signiﬁcant 5-year decline was found in Estonia and Latvia, and
increases were found in Armenia, Georgia, and Ukraine. In
2011, the highest number of newly diagnosed HIV cases
reported to the ECDC from the East was in Ukraine (38.0/
100 000), followed by Estonia (27.3/100 000) [2]. The Russian
Federation reported 67 317 new HIV cases in 2011. The
male-to-female ratio ranged from 1.1 in Belarus and Moldova
to 4.1 in Lithuania. The most common transmission mode was
heterosexual transmission (56.7%), followed by injection drug
use (37.6%).
In the year 2011, 6282 AIDS cases and 1359 deaths from
AIDS were reported (Table 1). The most common AIDS
indicator disease in 2011 was pulmonary tuberculosis (diag-
nosed in 36.1% of AIDS cases), followed by wasting syndrome
and oesophageal candidiasis.
In the Baltic, the number of reported HIV cases in Estonia
dropped from the high level of 66.0/100 000 in 2002 to 27.3/
100 000 in 2011 [2,3]. In 2011, 65.3% of cases had an unknown
mode of transmission and/or transmission mode other than
injection drug use, sex between men, heterosexual transmis-
sion, or mother-to-child transmission, and 18.9% of cases were
reported as in IDUs [2]. RDS surveys conducted in IDUs in
Tallinn from 2005 found an HIV prevalence of slightly over 50%
(54% in 2005, 55% in 2007, and 51% in 2009). However, the
HIV prevalence declined among new injectors (34% in 2005,
and 16% in 2009), reﬂecting the implementation of an
expanded needle and syringe exchange programme [23]. An
HIV data triangulation project also found evidence for a decline
in HIV transmission since mid-2000 [24].
Latvia reported 13.4 HIV cases per 100 000 population in
2011, the most frequent mode of transmission being hetero-
sexual transmission (48.2%), followed by injection drug use
(30.1%) [2]. Nonetheless, a study based on modelling and
phylogenetic analyses revealed that more than half of the cases
of heterosexual transmission in Latvia were caused by IDUs
[25]. The highest measured HIV prevalence in 2011 was in
FSWs (22.2%); the prevalence rates among IDUs and MSM
were 11.2% and 7.8% [26].
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In Ukraine, heterosexual transmission predominated among
reported HIV cases in 2011 (59.1%), followed by injection drug
use (38.0%) [2]. The highest HIV prevalence assessed in
surveys in 2011 was in IDUs (21.5%, 2.5–43.8% per city),
followed by FSWs (9.0%, 0–38.2% per city) and MSM (6.4%, 0–
20.0% per city) [27]. In 2011, the HIV prevalence in pregnant
women was 0.47%, although there were substantial regional
variations, from 0.02% in the Zakarpattya region to 1.08% in
Dnipropetrovsk. In spite of increases in the numbers of
reported HIV cases in Ukraine in the past 10 years, the
recently conducted HIV data triangulation study found evi-
dence for a declining HIV incidence among IDUs and the
potential for HIV spread among MSM, owing to low prevention
coverage [28]. Additionally, it was found that male IDUs and
MSM may be misclassiﬁed as heterosexual men in the case
reporting system.
According to the Federal Statistics Agency of the Russian
Federation, and as reported by the ECDC, 67 317 new HIV
cases were registered in the Russian Federation in 2011 [2].
This is an increase as compared with the 62 581 cases
reported to the ECDC for 2010 [2]. According to the latest
available UNGASS report, in 2008–2009 the leading mode of
transmission was injection drug use (62%).
In 2008–2009, the HIV prevalence rates were 2.6–61.1% in
IDUs, 4.5–19.6% in FSWs, and 4.6–8.3% in MSM [29]. The HIV
prevalence in pregnant women in Russia in 2009 was 0.5% [29].
In 2011 in Moldova, the rate of reported HIV cases was
20.3/100 000, with a male-to-female ratio of 1.1 : 1 [2]. The
major reported mode of HIV transmission was heterosexual
(85.0%), followed by injection drug use (8.5%). The HIV
prevalence rates in IDUs in RDS surveys conducted in 2009 in
Chisinau and Balti were 12.6% and 39.0%, respectively,
whereas in the same cities they were 0.2% and 1.7% in MSM
[30]. RDS surveys performed in 2009–2010 in FSWs found
HIV prevalence rates of 6.9% in Chisinau and 24.7% in Balti
[31]. In spite of a high number of HIV cases being reported as
resulting from heterosexual transmission, a recently con-
ducted HIV data triangulation found that two-thirds of recent
HIV infections in 2010 resulted from transmission within and
from the most at-risk groups [32].
In the countries of the southern Caucasus (Armenia,
Azerbaijan, and Georgia), the rate of reported HIV cases
was four to six times larger in 2011 (per 100 000 population:
5.5, 6.0, and 9.5, respectively) than in 2002 [2,3]. The principal
mode of transmission in the region seems to be changing, as
the epidemic was initially concentrated in IDUs, whereas in
2011 the most common mode of HIV transmission was
heterosexual transmission in Armenia and Georgia (69.6% and
47.6%, respectively, of all HIV cases reported) and injection
drug use in Azerbaijan (57.6%). Consequently, the male-to-
female ratio in 2011 ranged from 1.7 : 1 in Armenia to 2.9 : 1
in Azerbaijan.
Surveys conducted among IDUs found prevalence rates of
HIV infection of 2–16.7% per site in 2011 in Azerbaijan and
10.7% in Armenia in 2010–2011 [33,34]. In RDS surveys
conducted in 2011 in IDUs in ﬁve cities in Georgia, the HIV
prevalence ranged from 1.5% to 4.4%. A higher HIV prevalence
of 6.4% was found in a survey in MSM in 2010 in Tbilisi
(Chikovani et al., Sixth IAS Conference on HIV Pathogenesis,
Treatment, and Prevention, 2011, Abstract TUPE480). Surveys
conducted among MSM in 2010 using RDS found a prevalence
of HIV infection in Azerbaijan of 0.4% (Suleymanova, FEMP
2011, Abstract TUPE480; http://www.smittskyddsinstitutet.se/
upload/femp/097_Multiple_Suleymanova_Javahir.pdf). The ﬁnd-
ing from Georgia and the male-to-female ratio raise concerns
that MSM behaviour is under-reported.
Transmitted Drug Resistance (TDR) in
Europe
Transmission of antiretroviral drug-resistant HIV strains from
treated individuals experiencing suboptimal suppression of
viral replication or virological failure to treatment-naive
individuals has been reported in the majority of European
countries.
The prevalence of TDR at a European level has been
systematically monitored since 2002 by the Strategy to
Control the Spread of HIV-1 (SPREAD) surveillance pro-
gramme, which is based on a representative cohort of newly
diagnosed individuals sampled within 6 months of diagnosis. A
SPREAD study that included 2793 individuals diagnosed with
HIV infection from 20 European countries and Israel estimated
the overall prevalence of TDR at 8.4% [35]. No time trend in
the prevalence of TDR and nucleoside reverse transcriptase
inhibitor (NRTI) resistance was observed during the study
period, whereas the prevalence of TDR to protease inhibitors
(PIs) and non-nucleoside reverse transcriptase inhibitors
(NNRTIs) signiﬁcantly decreased. Infection with subtype B
was the strongest predictor for transmission of resistance in
SPREAD participants [35]. Recently, Frentz et al. [36]
reviewed 215 studies published up to 2009 on the epidemi-
ology of HIV-1 TDR that included 43 170 patients from
different continents and showed the following prevalence
rates: North America, 12.9%; Europe, 10.9%; Latin America,
6.3%; Africa, 4.7%; and Asia, 4.2%. An analysis of European
studies (n = 82, 25 446 patients, 75 studies from western
Europe) showed a 7.4% prevalence of TDR to NRTIs, a 3.4%
prevalence of TDR to NNRTIs, and a 2.9% prevalence of TDR
to PIs. Time trend analysis showed a decrease in the
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prevalence of TDR over time in Europe (11.5% in 2003,
decreasing to 7.7% after that year), which can be attributed to
the decline in resistance to NRTIs (from 8.0% to 4.3%) and PIs
(from 3.3% to 1.4%). In contrast, the prevalence of TDR to
NNRTIs showed little change in the same period of time (from
2.9% to 3.2%) [36,37].
However, more recent data on the prevalence of TDR in
Europe are available in a number of national and regional
studies (Table 2) [35,38–62]. Analysis of TDR prevalence
according to drug classes shows that the majority of
surveillance drug resistance mutations observed in newly
diagnosed individuals are associated with NRTI resistance
[35,38–62]. Nevertheless, the prevalence of TDR to NRTIs is
below 10% in the majority of European national studies
(Table 2). TDR to PIs and multiclass TDR have been rarely
observed in Europe in recent years. However, one should be
cautious in comparing different studies, because of many
methodological issues, including variations in how mutations
were deﬁned [63,64].
The reported prevalence of TDR in Europe in individuals
diagnosed with HIV infection since 2005 ranges between 0%
and 25%. An important contribution of transmission clusters
to the spread of resistant virus (particularly among MSM
carrying T215 revertants, and Y181C and M41L mutations) has
been described in several countries and regions within
countries (Sweden, Denmark, Greenland, Italy, Croatia,
northern Greece, the Basque Country in Spain, and Geneva)
[38–40,44,47,49,61]. Although subtype B infection was a
signiﬁcant predictor of TDR in the SPREAD study and several
more recent national studies (Croatia and Italy), other studies
have found a comparable risk of TDR in subtype B and
non-subtype B infections (France) [42,53,61].
Comment
Notable changes are occurring in HIV epidemics across
Europe. In the West, the trends in reported HIV cases vary.
Whereas declines since 2007 have been noted in The
Netherlands, Ireland, Portugal, Switzerland, and the UK,
increases have been observed in Belgium, Greece, and Iceland.
Nonetheless, HIV case reporting data cannot be reliably used
to interpret the trends in recent HIV infections, as they
depend on patterns of HIV testing and reporting practices.
Thus, the study in the UK found no decrease in the HIV
incidence in MSM in the period 2001–2010, whereas inci-
dence-based surveillance suggests that 16% of people newly
diagnosed with HIV in 2011 had been infected recently (in the
previous 4–6 months) [9,10]. In Paris, France, the ﬁrst
community-based survey on recent HIV infections in MSM
found a high HIV incidence of 3.8% person-years in spite of a
high uptake of HIV testing, whereas the HIV prevalence was
17.7% [65,66]. Another study conducted in France estimated
that the time between HIV infection and diagnosis ranged from
37.0 months for MSM to 53.0 months for heterosexual men,
implying the need to scale up HIV testing [67].
In the countries where estimates of recent infections are
not available, the changes in the reported cases have to be
interpreted in the context of the changes in the number of HIV
tests performed, although such data are rarely available for the
countries of the West in the ECDC reports. Of note is a low
and decreasing number of HIV tests performed in Greece
since 2007 (in 2011, the testing rate was 1.1/1000), whereas in
Austria, Belgium and Ireland the numbers of tests have
increased since 2007 [2].
In the Centre, the number of cases reported since 2007
increased signiﬁcantly in Bulgaria and Turkey. In some of the
countries in the Centre, the numbers of HIV tests increased
markedly. For example, in Albania, 1.6/1000 tests were
performed in 2000, as compared with 30.5/1000 in 2011
[2,68]. In Bulgaria, the testing rate almost doubled from 2000
to 2011 (from 12.8/1000 to 24.0/1000), and in Turkey it
increased from 14.1/1000 in 2002 to 25.7/1000 in 2006
[2,68,69]. Cyprus had a relatively high HIV testing rate
according to the most recent available data (53.6/1000 in
2008), but there are no HIV prevalence data for groups at
higher risk [70]. According to the available data, although they
are often of insufﬁcient quality, the HIV prevalence continues
to be relatively low in all key vulnerable groups in the
examined countries of the Centre, with the exception of IDUs
in Bulgaria [15,17,21,22,71–73].
In the East, Armenia, Georgia and Ukraine recorded a
signiﬁcant rise in the number of HIV cases since 2007, whereas
the rate declined in Estonia and Latvia. Georgia and Latvia are
the only countries in the East where HIV testing decreased
from 2011 to 2002. The increase in HIV testing was high in
Armenia (1.3/1000 in 2001 and 21.0/1000 in 2011), Azerbaijan
(13.0/1000 in 2002 and 40.1/1000 in 2011), Belarus (37.1/1000
in 2002 and 99.0/1000 in 2011), and Moldova (14.1/1000 in
2002 and 51.6/1000 in 2006) [2,69,74,75]. In Estonia, it
increased from 42.6/1000 in 2002 to 63.4/1000 in 2011
[2,69]. However, it is not known to what extent the increase
in testing rate reﬂects the increase in testing in the groups
most at risk of HIV, and this applies to all of the countries
included in this review [2].
In all countries of the East described in this review (with the
exception of Georgia), the HIV burden is high in IDUs and fuels
heterosexual HIV transmission. Although there is no evidence
of generalized HIV transmission in the East, the signiﬁcance of
sexual HIV transmission is substantial.
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TABLE 2. The prevalence of transmitted drug resistance (TDR) in human immunodeﬁciency virus (HIV)-infected individuals
from Europe (selected national studies including patients who were sampled after 2004)
Country or region
Number of participants
and year of sampling
Overall prevalence
of TDR Restance by ARV class Comment Reference
SPREAD study
20 European countries and Israel N = 2793
(2002–2005)
8.4% NRTI: 4.7%
NNRTI: 2.3%
PI: 2.9%
No time trend in the
prevalence of TDR and
RTI resistance
Vercauteren et al. [35]
National studies from western Europe
Denmark N = 1405
(2001–2009)
6.1% NRTI: 2.9%
NNRTI: 1.3%
PI: 2.6%
Dual class TDR: 14%
of patients with TDR
Resistant viruses carrying
215 revertant SDRMs
in transmission chains
Audelin et al. [44]
Greenland N = 60
(1999–2007)
25% NRTI: 23%
PI: 10%
Dual class TDR: 6/15
patients with TDR
Contribution of
transmission strains to
the spread of resistant
viruses
Madsen et al. [38]
France N = 466
(2006–2007)
10.6% NRTI: 5.8%
NNRTI: 2.8%
PI: 4.7%
42% of non-B subtype
infections Comparable
TDR in B and non-B
subtypes
Descamps et al. [42]
Germany N = 2078
(2001–2009)
9.2% NRTI: 5.8%
NNRTI: 2.8%
PI: 2.7%
A study focusing on
chronically infected
patients Declining
prevalence of TDR in
2008 and 2009
Oette et al. [55]
Ireland N = 856
(2004–2008)
6.3% Single class resistance: 5.7%
Dual class resistance: 0.5%
Triple class resistance: 0.1%
69/856 patients with
SDRM in RT region
12/756 patients with
SDRM in PI region
The majority of TDR was
in Irish-born individuals
with subtype B infection
De Gascun et al. [58]
Northern Greece N = 369
(2000–2007)
12.5% NRTI: 7.6%
NNRTI: 5.4%
PI: 3.3%
Dual class resistance: 3.8%
Infection with subtype A
was a predictor of TDR
Transmission clusters of
patients infected with
a T215 revertant HIV
strain with Y181C
mutations
Skoura et al. [47]
Italy N = 169
(1998–2009)
15.4% NRTI: 11.8%
NNRTI: 6.5%
PI: 7.1%
A study limited to
individuals infected
with theF1 subtype
Franzetti et al. [54]
Italy 3163
(2000–2010)
12% Non-acute non-recent
infection (n = 2937):
NRTI: 7.4%
NNRTI: 5%
PI: 9.9%.
Acute or recent
infection (n = 226):
NRTI: 7%
NNRTI: 7%
PI: 3%
Subtype C vs. subtype B
infection predicted
lower odds of TDR TDR
declined overall and for
the single drug classes
Colaﬁgli et al. [53]
Sicily N = 108
(2004–2008)
15.7% NRTI: 10.2%
PI: 2.8%
K103N was the most
frequently found SDRM
Bonura et al. [52]
Spain N = 1864
(2007–2010)
8.6% NRTI: 3.9%
NNRTI: 3.9%
PI: 2.3%
15.9% of non-B subtypes Monge et al. [50]
Basque Country, Spain N = 261
(2004–2007)
11.1% NRTI: 7.6%
NNRTI: 2.3%
PI: 0.4%
PI + NNRTI: 0.4%
NRTI + NNRTI: 0.4%
84.3% of subtype B
infections Transmission
cluster of individuals
carrying T215D revertant
SDRM, mostly MSM
Cuevas et al. [40]
Sweden N = 1463
(2003–2010)
5.6% 68% of TDR patients had
single class resistance
Five patients had
multiclass resistance
TDR signiﬁcantly
associated with MSM
group and subtype B
infection A cluster of
MSM carrying M41L
SDRM from
Stockholm TDR
concentrated among
MSM, clustering of
TDR strains
Karlsson et al. [49]
UK N = 14 584
(2002–2009)
11.3% 2007: NRTI 5.4%, PI 1.5%
2009: NRTI 6.6%, PI 2.1%
A study focusing on
subtype B infections that
were probably acquired in
the UK) T215 revertants
were the most frequent
mutations associated with
NRTI TDR
UK Collaborative
Group on HIV Drug
Resistance [51]
Geneva, Switzerland N = 637
(2000–2008)
8.5% NRTI: 6.3%
NNRTI: 3.5%
PI: 1.9%
Transmission clusters were
more frequent in
individuals with TDR than
in those with
sensitive strains
Yerly et al. [39]
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It is encouraging that several countries in the East with a
high burden of HIV (Estonia, Moldova, and Ukraine) carried
out HIV data triangulation and synthesis, which enabled better
characterization of the epidemic. Such projects are particularly
important in the East and the Centre, where HIV inci-
dence-based surveillance has not been established and where
HIV case reporting data provide biased information about
modes of transmission. In such circumstances, popula-
tion-based HIV bio-behavioural surveys in the groups most
at risk provide more valid data on the burden of infection and
the need for various HIV interventions.
Because of the availability and early introduction of
antiretroviral therapy, there has been a marked decline in
new AIDS cases and HIV-related mortality in the West.
However, the number of AIDS cases and the associated
mortality in the East is still increasing, mainly because of low
treatment coverage [1,2]. Tuberculosis is a prevalent disease in
HIV-infected people in the East, and is still a major cause of
mortality among people living with HIV/AIDS [1,2]. Many of
the WHO high-priority countries for tuberculosis control
(Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia,
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova,
Romania, Russian Federation, Tajikistan, Turkey, Turkmenis-
tan, Ukraine, and Uzbekistan) are in the eastern part of the
European Region, and many of those countries also have an
increasing HIV epidemic or already have a high burden of HIV
cases. HIV testing coverage of tuberculosis patients in the
whole European Region is still inadequate; it is estimated to be
60% [76]. Hence, tuberculosis is still an important public health
issue in Europe, and tuberculosis–HIV co-infection requires
good coordination within the healthcare system and prompt
provision of both HIV and tuberculosis care and treatment.
Late presentation to care occurs in the whole European
Region; an expansion of testing and the introduction of
different testing strategies are urgently needed. One of the
limitations in comparing the number of newly reported HIV
cases across the European Region lies in the fact that the
validity of these data strongly depends on the patterns of HIV
testing, the accessibility of HIV testing for the groups most at
risk of HIV, and the reporting of HIV cases.
The fact that sex between men is stigmatized in many
European countries not only affects testing rates, access to
early HIV diagnosis, and the overall wellbeing of MSM, but may
also result in under-reporting of such behaviour in the
surveillance system [71,72]. We suspect that, in countries
with a high male-to-female ratio and a large number of
heterosexual or unknown HIV transmissions, sex between
men was mainly not disclosed.
Table 2 (Continued)
Country or region
Number of participants
and year of sampling
Overall prevalence
of TDR Restance by ARV class Comment Reference
Israel N = 148
(2002–2009)
15.5% NRTI: 6.7%
NNRTI: 6%
PI: 4.7%
A study focusing on HIV-
infected MSM
Levy et al. [59]
National studies from eastern Europe
Estonia N = 145
(2008)
5.5% NRTI: 2.8%
NNRTI: 2.1%
PI: 2.8%
Dual class TDR: 2%
85% of infections with
CRF06_cpx
Avi et al. [48]
Georgia N = 126
(2006–2008)
3.9% NRTI: 2.4%
PI: 1.6%
90.2% of subtype A
infections clustered with
Former Soviet Union
A subtype
Dvali et al. [56]
Latvia N = 117
(2005–2006)
3.4% NRTI: 0.8%
NNRTI: 0.8%
PI: 1.6%
20% of national coverage in
the two selected years
Balode et al. [41]
National studies from central Europe
Croatia N = 118
(2006–2008)
22.0% NRTI: 19.5%
NNRTI: 2.5%
Transmission cluster of
subtype B individuals
carrying T215S mutation
(mostly MSM)
Grgic et al. [61]
Cyprus N = 53
(2007–2009)
No resistance No resistance 48.6% of subtype B, 18.9%
of subtype A
Kousiappa et al. [45]
Slovenia N = 150
(2005–2010)
4.7% NRTI: 2%
NNRTI: 2%
PI: 0.7%
89% of subtype B TDR
limited to MSM
Lunar et al. [62]
Romania N = 61
(1997–2011)
14.8% NRTI: 13.1% Declining TDR trend in the
period 2005–2011
Temereanca et al. [60]
Poland N = 95
(2008)
5.3% NNRTI: 1.1%
PI: 4.2%
TDR limited to single
classes of antiretroviral
drugs
Stanczak et al. [43]
Hungary N = 30
(2008–2010)
16.6% NRTI: 10%
NNRTI: 6.6%
29 of 30 subtype
B infections
Mezei et al. [46]
Istanbul (Turkey) N = 20 4 patients Mutations causing
resistance to NRTIs,
NNRTIs and PIs
were detected
HIV subtype diversity
(B, A1, C, CRF02_AG,
CRF03_AB, CRF06_cpx)
Alpsar et al. [57]
ARV, antiretrovirals; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitors; RT, reverse transcriptase;
SDRM, surveillance drug resistance mutation; SPREAD, Strategy to Control the Spread of HIV-1.
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In terms of TDR, literature data suggest high heterogeneity
in the prevalence of TDR in Europe at the regional level,
particularly in the context of the local HIV molecular diversity
and the contribution of transmission clusters to the spread of
resistant viruses in closed populations.
In conclusion, effective and repeated surveillance in IDUs,
MSM and FSWs and bridging groups needs strengthening in all
regions of Europe, particularly in the countries where there is
evidence for increases in the numbers of diagnosed HIV cases
and where population-based HIV data are lacking. There are
encouraging signs that HIV prevention interventions are
making an impact on HIV transmission in several countries.
However, the HIV epidemic continues to grow in most parts
of Europe, driven by high levels of risky behaviour and
insufﬁcient provision of and access to HIV prevention and
treatment services.
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